Tenapanor
- Generic Name
- Tenapanor
- Brand Names
- Ibsrela
- Drug Type
- Small Molecule
- Chemical Formula
- C50H66Cl4N8O10S2
- CAS Number
- 1234423-95-0
- Unique Ingredient Identifier
- WYD79216A6
- Background
Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class and therefore ex...
- Indication
Tenapanor is indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in adults.
...
- Associated Conditions
- Chronic Kidney Disease (CKD), Irritable Bowel Syndrome With Constipation (IBS-C)
- Associated Therapies
- -
A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 312
- Registration Number
- NCT02727751
- Locations
- ๐บ๐ธ
Ardelyx Clinical Site, Miami, Florida, United States
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 593
- Registration Number
- NCT02686138
- Locations
- ๐บ๐ธ
Ardelyx Investigative Site 257, Dothan, Alabama, United States
๐บ๐ธArdelyx Investigative Site 288, Miami, Florida, United States
๐บ๐ธArdelyx Investigative Site 138, Atlanta, Georgia, United States
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 219
- Registration Number
- NCT02675998
- Locations
- ๐บ๐ธ
Ardelyx Investigative Site 409, Brookhaven, Mississippi, United States
๐บ๐ธArdelyx Investigative Site 402, Kalamazoo, Michigan, United States
๐บ๐ธArdelyx Investigative Site 401, Saint George, Utah, United States
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
- Conditions
- Interventions
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 606
- Registration Number
- NCT02621892
- Locations
- ๐บ๐ธ
Ardelyx Investigative Site 137, Norcross, Georgia, United States
๐บ๐ธArdelyx Investigative Site 278, Hagerstown, Maryland, United States
๐บ๐ธArdelyx Investigative Site 135, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.